Uptake of screening and prevention in women at very high risk of breast cancer

Lancet. 2001 Sep 15;358(9285):889-90. doi: 10.1016/S0140-6736(01)06039-1.


Management of women at high lifetime risk of familial breast cancer is hampered because of limited data concerning the appropriateness of treatment options. Over the past 8 years women at very high (>40%) lifetime risk of breast cancer have had the option of entering two chemoprevention treatment trials, a magnetic resonance imaging (MRI) breast screening study, or a risk-reducing mastectomy (RRM) study. Only 10% of eligible women have entered one of the chemotherapy trials with a similar proportion opting for RRM (>50% in mutation carriers) compared with 60% opting for MRI screening. Future chemotherapy trials will have to be designed to address this poor recruitment.

Publication types

  • Letter

MeSH terms

  • Adult
  • BRCA2 Protein
  • Breast Neoplasms / genetics
  • Breast Neoplasms / prevention & control*
  • Breast Neoplasms / surgery
  • Female
  • Genes, BRCA1 / genetics
  • Humans
  • Magnetic Resonance Imaging
  • Mass Screening / methods
  • Mastectomy
  • Middle Aged
  • Neoplasm Proteins / genetics
  • Risk Factors
  • Transcription Factors / genetics


  • BRCA2 Protein
  • Neoplasm Proteins
  • Transcription Factors